Checkpoint Therapeutics Inc - ESG Rating & Company Profile powered by AI
This SDG assessment for Checkpoint Therapeutics Inc represents the company's reporting of the UN Sustainable Development Goals. Complete Sustainability assessment of Checkpoint Therapeutics Inc are reached by registering for free. Alternative corporations in the rating peer group for Checkpoint Therapeutics Inc are shown below.
Checkpoint Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 2.7, social score of 3.2 and governance score of 6.0.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | Checkpoint Therapeutics Inc | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Checkpoint Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Checkpoint Therapeutics Inc disclose current and historical energy intensity?
Does Checkpoint Therapeutics Inc report the average age of the workforce?
Does Checkpoint Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Checkpoint Therapeutics Inc disclose its ethnicity pay gap?
Does Checkpoint Therapeutics Inc disclose cybersecurity risks?
Does Checkpoint Therapeutics Inc offer flexible work?
Does Checkpoint Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Checkpoint Therapeutics Inc disclose the number of employees in R&D functions?
Does Checkpoint Therapeutics Inc conduct supply chain audits?
Does Checkpoint Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Checkpoint Therapeutics Inc conduct 360 degree staff reviews?
Does Checkpoint Therapeutics Inc disclose the individual responsible for D&I?
Does Checkpoint Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Checkpoint Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Checkpoint Therapeutics Inc disclose water use targets?
Does Checkpoint Therapeutics Inc have careers partnerships with academic institutions?
Did Checkpoint Therapeutics Inc have a product recall in the last two years?
Does Checkpoint Therapeutics Inc disclose incidents of discrimination?
Does Checkpoint Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Checkpoint Therapeutics Inc issued a profit warning in the past 24 months?
Does Checkpoint Therapeutics Inc disclose parental leave metrics?
Does Checkpoint Therapeutics Inc disclose climate scenario or pathway analysis?
Does Checkpoint Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Checkpoint Therapeutics Inc disclose the pay ratio of women to men?
Does Checkpoint Therapeutics Inc support suppliers with sustainability related research and development?
Does Checkpoint Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Checkpoint Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Checkpoint Therapeutics Inc involved in embryonic stem cell research?
Does Checkpoint Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Checkpoint Therapeutics Inc disclose its waste policy?
Does Checkpoint Therapeutics Inc report according to TCFD requirements?
Does Checkpoint Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Checkpoint Therapeutics Inc disclose energy use targets?
Does Checkpoint Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Checkpoint Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Checkpoint Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.